Dr. Kopetz on the Correlation Between Tumor Sidedness and Biomarkers in CRC

Scott Kopetz, MD, PhD, FACP
Published: Thursday, Jun 06, 2019



Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the correlation between tumor sidedness and biomarkers in colorectal cancer (CRC).

There is continued work to try to understand the relationship between the location of the tumor and significant biomarkers in CRC, Kopetz says. For example, integrating sidedness into the understanding of molecular alterations and other epigenetic features such as microRNAs is still an unanswered question. Researchers are beginning to see that tumor sidedness involves a lot of the biomarkers that are seen in CRC.

Sidedness is a unique biomarker in that by determining the location of the tumor, physicians can understand a lot of the disease’s biological features. Kopetz concludes that several ongoing studies are trying to dissect out how much of the biology can be attributed purely to the location of the tumor.
SELECTED
LANGUAGE


Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the correlation between tumor sidedness and biomarkers in colorectal cancer (CRC).

There is continued work to try to understand the relationship between the location of the tumor and significant biomarkers in CRC, Kopetz says. For example, integrating sidedness into the understanding of molecular alterations and other epigenetic features such as microRNAs is still an unanswered question. Researchers are beginning to see that tumor sidedness involves a lot of the biomarkers that are seen in CRC.

Sidedness is a unique biomarker in that by determining the location of the tumor, physicians can understand a lot of the disease’s biological features. Kopetz concludes that several ongoing studies are trying to dissect out how much of the biology can be attributed purely to the location of the tumor.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x